Avricore Health stock analysis
Want to see TSE:AVCR full AI Analyst Report?
Avricore Health (AVCR) Stock Price & Analysis
AVCR Stock Chart & Stats
- Day’s Range
- CAD 0.05 - CAD 0.05
- 52-Week Range
- CAD 0.04 - CAD 0.10
- Previous Close
- CAD 0.05
- Volume
- N/A
- Average Volume (3M)
- 44.49K
- Market Cap
- CAD 5.69M
- Enterprise Value
- CAD 5.89M
- Total Cash (Recent Filing)
- CAD 922.55K
- Total Debt (Recent Filing)
- CAD 0
- Price to Earnings (P/E)
- ―
- Beta
- 1.33
- Next Earnings
- Nov 26, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
Essentially no debt gives Avricore greater financial flexibility and removes near-term interest and refinancing pressure. This can help preserve resources for operating needs and platform development, although the benefit is limited while losses continue to weaken the equity base.
Historical Operating Cash Generation
Positive operating cash flow in 2023 and especially 2024 shows that the business has previously demonstrated an ability to convert operations into cash. That history provides evidence of potential operating leverage if revenue and margins recover, despite the latest deterioration.
Pharmacy-based Care Platform
HealthTab is positioned within pharmacy-based point-of-care diagnostics and supports preventative care and chronic disease management. This service model can embed Avricore in community healthcare workflows and give the platform durable relevance if adoption expands.
Bears Say
Severe Revenue Deterioration
The sharp revenue contraction materially reduces operating scale and weakens the foundation for recovering fixed costs. A very low current revenue base also makes future results more volatile, leaving the company dependent on successfully rebuilding demand and commercial activity.
Negative Profitability
Negative gross profit indicates that current revenue does not cover the direct economics of the business, while widening operating and net losses show pressure beyond the gross margin line. Sustained losses can erode shareholder equity and constrain investment capacity.
Negative Recent Cash Flow
Recent cash consumption increases the company’s funding risk even without debt, because operations are not currently supplying the cash needed to sustain the business. Continued negative operating and free cash flow could limit flexibility and require corrective action.
Avricore Health News
AVCR FAQ
What was Avricore Health’s price range in the past 12 months?
What is Avricore Health’s market cap?
When is Avricore Health’s upcoming earnings report date?
How were Avricore Health’s earnings last quarter?
Is Avricore Health overvalued?
Does Avricore Health pay dividends?
What is Avricore Health’s EPS estimate?
How many shares outstanding does Avricore Health have?
What happened to Avricore Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Avricore Health?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Avricore Health
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Rodger Seccombe
- Employees
- 26
- Website
- www.avricore.com
- Address
- 700 – 1199 West Hastings Street, Vancouver, BC, V6E 3T5, CA
Avricore Health (AVCR) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 1 | 11 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| TSE:BUXBioMark Diagnostics | ||
| TSE:TELOTelo Genomics Corp | ||
| TSE:SZLS.HStageZero Life Sciences Ltd | ||
| TSE:NARAPanGenomic Health, Inc. Class A |










